XNASLPTX
Market cap117mUSD
Jan 10, Last price
3.06USD
1D
-9.60%
1Q
32.47%
Jan 2017
-77.88%
IPO
-96.11%
Name
Leap Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
69.97%
Rev. gr., 5y
0.00%
Revenues
0k
Net income
-81m
L+49.12%
CFO
-44m
L-10.79%
Earnings
Mar 17, 2025
Profile
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 87,041 | 57,178 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (87,041) | (57,178) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 147 | ||||||||
Tax Rate | |||||||||
NOPAT | (87,041) | (57,325) | |||||||
Net income | (81,414) 49.12% | (54,596) 34.52% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (1,000) | (210) | |||||||
BB yield | 0.00% | 4.12% | |||||||
| Debt | |||||||||
Debt current | 524 | 416 | |||||||
Long-term debt | 262 | 940 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (69,857) | (64,144) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (43,753) | (49,044) | |||||||
CAPEX | |||||||||
Cash from investing activities | 48,969 | ||||||||
Cash from financing activities | (30) | (210) | |||||||
FCF | (86,614) | (57,519) | |||||||
| Balance | |||||||||
Cash | 70,643 | 65,500 | |||||||
Long term investments | |||||||||
Excess cash | 70,643 | 65,500 | |||||||
Stockholders' equity | (399,450) | (317,941) | |||||||
Invested Capital | 460,115 | 377,485 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 20,445 | 11,324 | |||||||
Price | 4.15 821.11% | 0.45 -86.11% | |||||||
Market cap | 84,745 1,563.05% | 5,096 -81.67% | |||||||
EV | 14,888 | (59,048) | |||||||
EBITDA | (87,026) | (57,162) | |||||||
EV/EBITDA | 1.03 | ||||||||
Interest | 54 | ||||||||
Interest/NOPBT | |||||||||